Rheumatologist

111 River Street, Mailstop 8-02

Hoboken, NJ 07030-5774

klosavio@wiley.com

WRITER GUIDELINES

Thank you for writing for us. We appreciate all the effort, thought, research, and skill that go into writing a good article. We value all your hard work and your contributions to the success of our publication. Here are a few submission tips:

- Submit your article in Microsoft Word format via e-mail to **klosavio@wiley.com**. Use 12-point, Times New Roman type.
- Include a headline and byline in your document. Also, at the end of the document, include the full name, degrees, title, and affiliation with city and state for yourself and all co-authors.
- Don't use:
 - o Double spaces between words.
 - Embedded references (instead manually insert the numbers as superscript numbers, with a numbered reference list at the end of the article).
 - o Abbreviations.
 - o All caps in running text.
- Do use:
 - Credentials after the first complete reference to a source (e.g., Simon Helfgott, MD, and thereafter Dr. Helfgott).
 - The AMA Manual of Style when creating your reference section.
 - o Double-line spacing throughout.
 - o Present-tense throughout (e.g., "Dr. Helfgott says" instead of "Dr. Helfgott said").
 - o Generic names for drugs, etc. If necessary, the brand name may be included in parentheses after the generic name on first use. *Exception:* When referring to a biosimilar use both the biosimilar name and the name of the reference product.
 - ➤ FDA approved: Inflectra (infliximab-dyyb), biosimilar to Remicade (infliximab)
 - > FDA approved: filgrastim-sndz (Zarxio), biosimilar to filgrastim (Neupogen), a cancer drug
 - ➤ Not yet approved: SB5, an adalimumab biosimilar, with adalimumab reference product (Humira)
 - o The % symbol and not the word percent with numerical percentages (e.g., 5%).
 - o Words for the numbers one through nine, and numerals for 10 and above.
 - o Acronyms, but on first use spell out the words, followed by the acronym in

parenthesis [e.g., disease modifying anti-rheumatic drugs (DMARDs)].

- o These special words/spellings:
 - nonsteroidal
 - email
 - website
 - granulomatosis with polyangiitis NOT Wegener's granulomatosis
 - X-ray
 - DXA
 - phase III trial NOT Phase 3
- o High-resolution images. If you're submitting a photo, we accept both hard copy photos and also electronic images that are 300 dpi in resolution or greater at the size they will print.
- o Figures and tables. Please include captions for figures.
- o Acronyms, but on first use spell out the words, followed by the acronym in parenthesis [e.g., disease modifying anti-rheumatic drugs (DMARDs)].

Keri Losavio Editor, *The Rheumatologist* John Wiley & Sons

Home Office: 408-477-2611 (Pacific time)

e-mail: klosavio@wiley.com